Search the Newsreel

PODD SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Insulet (PO

Faruqi & Faruqi, LLP is reminding investors of the August 31, 2026 deadline to seek lead plaintiff status in a federal securities class action lawsuit against Insulet Corporation (NASDAQ: PODD). The lawsuit alleges that Insulet made false and misleading statements about defective manufacturing controls …

PODD INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Insulet (PODD) Investors of Securities Class Action Lawsuit Deadline on August 31, 2026

Faruqi & Faruqi, LLP is investigating potential claims against Insulet Corporation (NASDAQ: PODD) and reminds investors of the August 31, 2026 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit. The lawsuit alleges Insulet made false and/or misleading …

Non-operating income (total) of Insulet Corporation – HAM:GOV

This article provides financial data for Insulet Corporation (HAM:GOV) specifically focusing on its non-operating income (total). The data is presented within the context of the Hamburg Stock Exchange, though no specific values are listed in the provided content. It serves as a placeholder for …

Net current asset value per share of Insulet Corporation – HAM:GOV

This article displays the "Net current asset value per share" for Insulet Corporation (GOV) on the Hamburg Stock Exchange. The current financial data for the specified period is not available, showing "No trades" as the market is closed. The content primarily consists of navigation …

ETFs Investing in Insulet Corporation Stocks

This article lists various ETFs that hold Insulet Corporation (GOV) stocks, providing detailed information such as market value, weight, issuer, management style, focus, expense ratio, AUM, price, change percentage, relative volume, and 3-year NAV total return. The ETFs cover a range of investment styles …

ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Insulet Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – PODD

NEW YORK, Aug. 07, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Insulet Corporation (NASDAQ: PODD) between February 21, 2025 and May 26, 2026, inclusive (the “Class Period”), of the important August 31, …

PODD Shareholder Alert: Insulet Corporation Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law Firm

The Gross Law Firm has issued a shareholder alert for Insulet Corporation (NASDAQ: PODD) investors who purchased shares between February 21, 2025, and May 26, 2026. The lawsuit alleges that Insulet's manufacturing controls were defective, leading to a risk of safety violations. Investors are …

Insulet (PODD) Is Down 15.9% After Cutting 2026 Revenue Guidance on Type 2 Retention Strains

Insulet Corporation (PODD) saw its stock drop 21.9% after cutting its 2026 revenue outlook due to weaker retention and utilization among Type 2 diabetes users, despite strong overall Omnipod growth. The company reported Q2 2026 sales of US$801.7 million and net income of US$95.0 …

PODD Shareholder Alert: August 31, 2026 Lead Plaintiff Deadline in Insulet Corporation Securities Class Action - Contact SueWallSt

This article announces a lead plaintiff deadline of August 31, 2026, for a securities class action lawsuit against Insulet Corporation (NASDAQ: PODD). The lawsuit alleges that Insulet made misleading statements regarding its manufacturing quality after two voluntary medical device corrections led to significant drops …

Insulet (PODD) Stock Looks Undervalued As The Market Stays Cautious

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Insulet stock has fallen sharply over the past year, yet both its Discounted Cash Flow (DCF) intrinsic value estimate and market multiples currently point to …

Analysts’ Top Healthcare Picks: Insulet (PODD), Entrada Therapeutics Inc (TRDA)

This article highlights two healthcare stocks, Insulet (PODD) and Entrada Therapeutics Inc (TRDA), which have received bullish sentiments from analysts. Steven Lichtman of William Blair maintained a Buy rating on Insulet, while Myles Minter, also from William Blair, maintained a Buy rating on Entrada …

Insulet Valuation Attractive Despite Growth Reset Risk, RBC Says

RBC views Insulet's valuation as attractive despite potential risks associated with its growth strategy and upcoming competition. The article briefly mentions Insulet's challenges in serving Type 2 diabetes patients. Full access to the MT Newswires article requires a premium subscription.

Insulet Corp (PODD) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth Offset by Type 2 ...

Insulet Corp (PODD) reported strong Q2 2026 revenue growth of 23.5%, exceeding expectations, driven by demand for its Omnipod product. However, the company lowered its full-year U.S. Omnipod growth outlook due to worse-than-anticipated retention and utilization trends among Type 2 diabetes patients, which it …

Insulet Corporation Stock 12‑Month Price Target Cut to $225.45, Implies 35% Upside

Analysts have lowered the 12-month average price target for Insulet Corporation (PODD) stock from $232.3 to $225.45, with a range of $160 to $294 per share. This new target implies a 35% potential upside based on the Aug. 4 closing price. Despite the target …

Insulet (PODD) Stock Sinks As Type 2 Stumble Clouds Strong Growth

Insulet Reports Second Quarter 2026 Results

Insulet Corporation announced strong financial results for the second quarter of 2026, with revenue reaching $801.7 million, a 23.5% increase year-over-year. The growth was driven by a 24.6% rise in Omnipod revenue, reflecting expanding global access for its tubeless insulin pump technology, including launches …

Insulet Earnings: Solid Quarterly Results Give Way to Impending Deceleration in Second Half

Insulet Corporation (PODD) PT Lowered to $180 at Stifel

Stifel analyst Jonathan Block has lowered the price target for Insulet Corporation (NASDAQ: PODD) to $180.00 from $225.00. The analyst, however, maintained a previous rating for the company. This article is marked as premium content and requires a subscription to view the full details.

Insulet Stock Crashes as Tiny Guidance Cut Changes the Story

This article first appeared on GuruFocus. Insulet (NASDAQ:PODD), the company behind the Omnipod tubeless insulin pump, got hammered nearly 19% on Wednesday even after delivering a quarter that easily cleared Wall Street's bar. Revenue jumped to $801.7 million, up almost 23% in constant currency …

Insulet Corp. stock underperforms Wednesday when compared to competitors

Insulet Corp. (PODD) shares fell 20.12% on Wednesday, closing at $133.26. This decline occurred during a mixed trading session where the Dow Jones Industrial Average rose, but the S&P 500 Index fell. This marks the second consecutive day of losses for the stock.

Truist Securities Downgrades Insulet Corporation (PODD) to Hold

Truist Securities analyst Richard Newitter has downgraded Insulet Corporation (NASDAQ: PODD) from Buy to Hold, setting a new price target of $153.00. The article notes that further details are available to premium subscribers of StreetInsider.com.

Why Insulet (PODD) Shares Are Sliding Today

Insulet Corporation (PODD) shares dropped significantly after the company reported strong second-quarter results but issued a weaker-than-expected revenue forecast for the third quarter. While Q2 revenue and EPS beat estimates, the lower guidance for the upcoming quarter led to a sell-off. The stock has …

Insulet Gears Up to Face Heightened Competition in 2027

Insulet, known for its tubeless insulin pump, has enjoyed minimal direct competition for two decades, allowing it to achieve significant profitability. However, the company is preparing for heightened competition anticipated in 2027. This report highlights Insulet's business strategy and outlook in light of impending …

This Medtech Beat Earnings, but the Stock Is Having Its Worst Day in 17 Years

Insulet lowers its full-year revenue growth outlook, even after earnings and revenue handily beat expectations. Continue Reading

Oppenheimer downgrades Insulet stock rating on diabetes growth concerns

Oppenheimer downgraded Insulet Corporation (NASDAQ:PODD) to Perform from Outperform due to concerns over its growth outlook after revised guidance. The company lowered its fiscal 2026 U.S. growth forecast, attributing issues to execution challenges in Type 2 diabetes, while Oppenheimer views them as more structural. …

Insulet forecasts 2026 revenue growth of 20%-22% as it adjusts U.S. assumptions on type 2 retention

Earnings Call Insights: Insulet (PODD) Q2 2026 MANAGEMENT VIEW * Ashley McEvoy said the quarter delivered “strong revenue growth, expanding profitability and solid cash flow generation,” with total revenue up 23% year-over-year on a constant currency basis and results “exceeding our expectations.” * CEO …

Oppenheimer Downgrades Insulet Corporation (PODD) to Perform

Oppenheimer analyst Suraj Kalia has downgraded Insulet Corporation (NASDAQ: PODD) from Outperform to Perform. This decision was made on August 5, 2026, at 2:00 PM EDT. The article is a premium-only content piece, requiring a subscription to StreetInsider.com Premium for full access.

This Medtech Beat Earnings Estimates. It’s the Worst S&P 500 Stock Today.

Insulet lowers its full-year revenue growth outlook, even after earnings and revenue handily beat expectations. Continue Reading

Lost Money on Insulet Corporation (PODD)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

Levi & Korsinsky, LLP is encouraging Insulet Corporation (NASDAQ: PODD) investors who suffered losses to join a class action lawsuit. The lawsuit alleges that Insulet made misleading statements regarding the manufacturing quality and safety of its Omnipod devices between February 21, 2025, and May …

Insulet Corporation stock hits 52-week low at $127.56

Insulet Corporation's stock has fallen to a 52-week low of $127.56, representing a significant decline of nearly 40% over the past year. Despite this downturn and a recent outlook reduction for the U.S. market due to customer retention issues, analysts maintain a "Buy" rating …

Insulet Reports Second-Quarter Revenue Growth as Full-Year U.S. Omnipod Outlook Is Lowered

Insulet Q2 results pressure Tandem, DexCom (PODD:NASDAQ)

Insulet Corporation's Q2 results, which included a lowered full-year revenue outlook, caused its stock to hit a 52-week low. This downturn also impacted competitors Tandem Diabetes and Dexcom, sending their shares lower. The news suggests a challenging environment for medical technology companies specializing in …

Insulet (PODD) Reports Q2 Earnings: What Key Metrics Have to Say

For the quarter ended June 2026, Insulet (PODD) reported revenue of $801.7 million, up 23.5% over the same period last year. EPS came in at $1.66, compared to $1.17 in the year-ago quarter. The reported revenue represents a surprise of +1.89% over the Zacks …

Insulet (PODD) Beats Q2 Earnings and Revenue Estimates

Insulet (PODD) reported strong Q2 earnings of $1.66 per share, surpassing the Zacks Consensus Estimate of $1.44, and revenues of $801.7 million, exceeding the $649.1 million from the previous year. Despite outperforming expectations for both earnings and revenue, the stock has seen a significant …

Why is Insulet stock tumbling today?

Insulet Corporation's stock tumbled 12.1% after the company released its Q2 2026 results, despite beating earnings expectations. The decline was primarily due to a meaningful cut in its full-year revenue growth forecast, driven by challenges in scaling its Omnipod platform into the type 2 …

Earnings Flash (PODD) Insulet Corporation Posts Q2 Adjusted EPS $1.66 per Share, vs. FactSet Est of $1.45

Insulet Corporation (PODD) reported its Q2 adjusted EPS at $1.66 per share, significantly exceeding FactSet's estimate of $1.45. This financial update indicates a stronger performance than anticipated by analysts for the medical device company. The article also lists recent news and analyst rating changes …